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The peroxisome proliferator-activated receptors (PPARs) are ligand activated nuclear receptors that
regulate cellular homoeostasis and metabolism. PPARs control the expression of genes involved in fatty-
acid and lipid metabolism. Despite evidence showing beneﬁcial effects of their activation in the treat-
ment of metabolic diseases, particularly dyslipidaemias and type 2 diabetes, PPAR agonists have also
been associated with a variety of side effects and adverse pathological changes. Agonists have been
developed that simultaneously activate the three PPAR receptors (PPARα, γ and δ) in the hope that the
beneﬁcial effects can be harnessed while avoiding some of the negative side effects.
In this study, the hepatic effects of a discontinued PPAR-pan agonist (a triple agonist of PPAR-α, -γ,
and -δ), was investigated after dietary treatment of male Sprague–Dawley (SD) rats. The agonist induced
liver enlargement in conjunction with metabolomic and lipidomic remodelling. Increased concentrations
of several metabolites related to processes of oxidation, such as oxo-methionine, methyl-cytosine and
adenosyl-methionine indicated increased stress and immune status. These changes are reﬂected in li-
pidomic changes, and increased energy demands as determined by free fatty acid (decreased 18:3 n3,
20:5 n3 and increased ratios of n6/n3 fatty acids) triacylglycerol, phospholipid (decreased and
increased bulk changes respectively) and eicosanoid content (increases in PGB2 and 15-deoxy PGJ2). We
conclude that the investigated PPAR agonist, GW625019, induces liver enlargement, accompanied by
lipidomic remodelling, oxidative stress and increases in several pro-inﬂammatory eicosanoids. This
suggests that such pathways should be monitored in the drug development process and also outline how
PPAR agonists induce liver proliferation.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Peroxisome proliferator-activated receptors, PPAR-α, PPAR-γ,
and PPAR-β/δ (PPAR-δ) are differentially expressed in various
tissues mediating numerous metabolic processes and globally
regulating systemic metabolism in mammals [1]. PPAR-α and
PPAR-δ have important roles in regulating β-oxidation in the liver
and skeletal muscle, respectively, while PPAR-γ is involved in the
sequestration of triglycerides to adipose tissue and overall adipose
tissue expandability [2,3]. The dominant effects of the three PPARs
are to a degree tissue speciﬁc. PPAR-α is mainly expressed in ther Inc. This is an open access article
il Human Nutrition Research,
bridge CB1 9NL, UK.
.L. Grifﬁn).liver, PPAR-γ is primarily expressed in adipose tissue whilst PPAR-
δ is ubiquitously expressed and abundant in most tissues [4–7].
However, all three receptors are present in the adult rat liver [4].
PPAR-α agonists have been used to reduce plasma triglyceride,
reduce low density lipoprotein cholesterol and increase high
density lipoprotein levels [8,9]. Their lipid lowering effects are in
part brought about by increased β-oxidation in the liver and
skeletal muscle [10]. In addition PPAR-α in part regulates liver
metabolism by increasing glycolysis and reducing gluconeogenesis
in the liver [11] and agonists have been shown to have potent
ability to decrease glucose concentrations in blood plasma [12].
PPAR-γ agonists improve insulin sensitivity [13,14] in part by sti-
mulating lipid uptake as well as de novo lipogenesis by adipocytes.
PPAR-γ agonists also cause increased glucose utilisation and de-
creased serum glucose levels without the need for increased in-
sulin secretion. In normal liver, PPAR-γ is expressed at a very lowunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Study design.
Group description Dose (mg/kg/day) Animal number Recovery animals
Control 0 1–12 13–18
Low 30 19–30 –
Intermediate 1 100 31–42 –
Intermediate 2 300 43–54 55–60
High 1000 61–72 73–78
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expression levels in steatotic liver [15]. PPAR-δ agonists have also
been shown to improve insulin resistance by increasing fatty acid
oxidation and reduce serum glucose levels [13]. Adverse ﬁndings
including apoptosis, inﬂammation and potentially carcinogenesis
have all been reported as a consequence of PPAR-δ activation.
There are however confounding reports regarding whether PPAR-
δ ligands promote or inhibit these effects depending on the ex-
perimental conditions used [16,17].
One of the proposed strategies for improving lipid metabolism
in metabolic diseases is to use a molecule which can simulta-
neously activate two or three PPAR receptors. It was hoped that
such PPAR-pan agonists would increase hepatic fatty acid oxida-
tion by stimulating PPAR-α and PPAR- δ, and further improve in-
sulin sensitivity by stimulating all three PPARs, and thus favour-
ably inﬂuence conditions associated with the metabolic syndrome
and type two diabetes mellitus (T2DM), whilst the negative effects,
such as increased adiposity caused by PPAR-γ leading to weight
gain would be negated by increased fat oxidation promoted by
PPAR-α and PPAR-δ.
The agonist was designed to simultaneously activate all three
isoforms of the PPARs to treat the metabolic syndrome. However,
this compound was withdrawn from development following the
induction of increased liver weight and myopathy in male Spra-
gue–Dawley (SD) rats. Although many of the metabolic regulatory
roles of PPARs have been clariﬁed, the reasons for their adverse
effects have remained elusive and currently, no triple (-pan) or
dual activators are on the market. Furthermore, by better deﬁning
these adverse effects we may be able to screen for PPAR agonists
that should be excluded early in the drug safety assessment
process.
Mechanism underlying the toxicity of PPAR-pan activation
most likely involve lipid-mediated processes, however, these are
yet to be deﬁned. With a better understanding of the pathophy-
siology that accompanies PPAR-pan agonists, it could become
possible to target activation of the beneﬁcial responses of PPAR
signalling without the pathological effects. In the present study a
comprehensive array of mass spectrometric approaches were used
in conjunction with multivariate statistics to deﬁne the metabolic
effects of a PPAR-pan agonist known to be associated with liver
enlargement and toxicity. Our results identify a dose responsive
decrease in triacylglycerol (TG) and increase in acyl-carnitine and
phospholipid concentrations, reﬂecting increased β-oxidation and
cell and/or organelle proliferation, respectively. These responses
are likely associated with targeting PPAR-α and PPAR-δ. There
were also increases in metabolites associated with processes of
oxidation, including oxo-methionine, methyl-cytosine and ade-
nosyl-methionine, further contributing to undesirable side effects
and potential DNA damage. In addition, dose dependent increases
were measured in the concentrations of inﬂammatory pros-
taglandins (PGs) 15d-PGJ2 and PGB2. Furthermore, we hypothesise
that the increased levels of inﬂammatory eicosanoids, which
themselves can act as endogenous PPAR activators [18], potentially
generate a positive feedback loop.2. Materials and methods
2.1. Animal experiments and study design
All animal studies were ethically reviewed and carried out in
accordance with Animals (Scientiﬁc Procedures) Act 1986 and the
GSK Policy on the Care, Welfare and Treatment of Animals.
PPAR-pan activator was administered to male Sprague–Dawley
rats (Crl:CD (SD) strain), 12 animals per group, by daily oral gavage
at 30, 100, 300, 1000 mg/kg/day for 13 weeks. A separate satellitegroup of animals (6 per group) were kept for a 4 week treatment
free period in the control, intermediate 2 (300 mg/kg/day) and
high (1000 mg/kg/day) dose groups (Table 1). According to the
principles of the 3Rs (replacement, reduction and reﬁnement)
recovery animals were not used for the low and for the inter-
mediate 1 dose groups.
2.2. Collection of samples
Blood and urine samples of all animals were collected in weeks
4, 13 and 18. At necropsy (at the end of dosing or following the
recovery period), tissue samples were collected following an
overdose of anaesthetic (halothane Ph. Eur. Vapour). Samples of
the liver were immediately removed, weighed, and sections snap-
frozen in liquid nitrogen. Samples were maintained at 80 °C
until further analysis. Tissue samples from all organ systems were
ﬁxed in neutral buffered formalin and process to slides. They were
examined by light microscopy for evidence of pathological
changes.
2.3. Analytical measurements
2.3.1. Extraction procedure
Brieﬂy, methanol: chloroform solution (2:1, 600 mL) was added
to approximately 50 mg of frozen tissue and homogenised with a
tissue lyser. Chloroform and water (200 mL each) was added,
samples were sonicated for 15 min and centrifuged (13,500 rpm,
20 min). The resulting aqueous and organic layers were separated
and the extraction procedure was repeated. Samples were dried
under nitrogen before processing for gas-chromatography–mass
spectrometry (GC–MS) and liquid chromatography–mass spec-
trometry (LC–MS). GC–MS, and LC–MS/MS methods for lipid ex-
traction and analysis were carried out according to methods pre-
viously described [19,20].
2.4. GC–MS analysis of fatty acid methyl esters (FAMEs)
For GC–MS, the resulting organic fractions from the chloro-
form: methanol extraction were used. Samples were reconstituted
in 1 mL of methanol:chloroform 2:1 and a ﬁfth of each sample
(200 mL) was transferred to a 3 mL glass vial. The 200 mL aliquots
were dried under nitrogen before being derivatised with a me-
thylating agent which forms fatty acid methyl esters (FAMEs) of
carboxylic acids. Chloroform:methanol (1:1, 100 μl), boron tri-
ﬂuoride in methanol (10 %, 125 μl) and 150 mL D-25-tridecanoic
acid (200 mM in chloroform) were added to the dried extracts.
Samples were vortex mixed and heated to 80 °C for 90 min. After
cooling, 300 mL water and 600 mL hexane were added. The samples
were vortex mixed, the lower aqueous layer was removed and the
remaining organic layer dried under nitrogen. The samples were
reconstituted in 150 μl hexane and transferred to autosampler
vials prior to analysis using a Trace GC Ultra coupled to a DSQ II
single-quadrupole mass spectrometer (Thermo Scientiﬁc, Hemel
Hempstead, Hertfordshire). Samples were injected onto a Zeb-
ron™ ZB-WAX column (100% polyethylene glycol 30 m0.25 mm
ID, 0.25 mm ﬁlm thickness). The injector temperature was 230 °C
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at 60 °C for 2 min, after which the temperature was increased to
150 °C at a rate of 15 °C/min, and ﬁnally increased to 240 °C at a
rate of 2.5 °C/min. The transfer line temperature was maintained
at 240 °C, while the ion source was at 250 °C, operating at 70 eV
for electron ionisation (EI). The detector was initiated after 240 s,
and full scan spectra were collected over a range of 50–650m/z.
2.5. Open proﬁling LC–MS/MS analysis of intact lipids
For LC–MS/MS analysis of lipids, the organic fractions of the
stock chloroform:methanol extraction were used. A 10 mL aliquot,
comprising one hundredth of the organic fraction, was diluted into
90 mL of methanol–chloroform (2:1) containing 20 mM 1,2-di-
heptadecanoyl-sn-glycero-3-phosphocholine (PC (17:0/17:0))
(Avanti Polar Lipids Inc., Alabaster, Alabama, US) The in-
strumentation comprised a Xevo G2 Quadrupole Time of Flight
(QToF) mass spectrometer with a Z-spray electrospray source
(Waters Ltd., Elstree, Hertfordshire, UK) coupled to an ACQUITY
Ultra Performance Liquid Chromatography (UPLC) system (Waters
Ltd., Elstree, Hertfordshire, UK). Separation of species was
achieved using an Acquity CSH C18, 1.7 mm (2.1100 mm) column
(Waters Ltd., Elstree, Hertfordshire, UK). Mobile phase A consisted
of 10 mM ammonium formate in acetonitrile:water (6:4), whilst
mobile phase B contained 10 mM ammonium formate in iso-
propanol:acetonitrile (9:1). The concentration of mobile phase B
was increased from 40% to 100% over 18 min, then equilibrated to
40% B for 2 min at a ﬂow rate of 0.4 mL/min. The electrospray
source was operated in positive ion mode with the source tem-
perature set at 80 °C and a cone gas ﬂow of 100 L/h. The deso-
lvation gas temperature was 250 °C and the nebuliser gas ﬂow rate
was set at 700 L/h. The capillary voltage was 3 kV and the cone
voltage 50 V. Mass spectrometric data were collected from 50 to
1200m/z in proﬁling scan mode. For structural elucidation, iden-
tiﬁcation and conﬁrmation of the lipid species present, data-de-
pendent acquisition (DDA) experiments were conducted using
pooled samples with ﬁve separate scan events. First, the mass
spectrometer was set to perform a full-scan, after which an MS/MS
scan on the most intense, the second, third and fourth most in-
tense ions was carried out. MS/MS was obtained at a scan rate of
0.6 s with a 0.05 s interscan delay and collision ramps from 20 to
40 eV and 25 to 50 eV. A dynamic exclusion window was set to
0.2 s. The MS scanning was switched to MS/MS acquisition when
the threshold value of 1000 intensity/s was exceeded. The MS/MS
returned to scanning mode when the signal of the total ion current
(TIC) fell below 1000 intensity/s or after 1 s.
Data were processed using MarkerLynx™ within the software
suite MassLynx™ (version 4.1) by Waters Ltd. (Elstree, Hertford-
shire, UK). Collection Parameters were set with a mass window of
0.05 Da and retention time window of 0.2 min. Data were auto-
matically deisotoped and normalised to the intensity of the in-
ternal standard. Tentative identiﬁcations were made based on
exact mass information using the Lipid Maps structure database
(Lipid Maps, La Jolla, California, US). DDA data was used to conﬁrm
or reject tentative IDs.
2.6. Targeted analysis of aqueous metabolites
For LC–MS/MS analysis aqueous phase metabolites resulting
from the chloroform:methanol extractions were used. The entire
fraction was dissolved in 300 ml of 70:30 acetonitrile:water con-
taining 20 mM universally 13C- and 15N- labelled glutamate. Sam-
ples were vortex mixed, sonicated, centrifuged, (17,000 g, 5 min)
pipetted into auto-sampler vials and analysed using an AB Sciex
5500 Qtrap mass spectrometer (AB Sciex UK Limited, Warrington,
Cheshire) coupled to a SIL20-A LC system (Shimadzu Corp., Kyoto,Japan). Mobile phase A consisted of 100 mM ammonium acetate,
mobile phase B was acetonitrile, and the ﬂow rate was 0.3 mL/min.
Two microliters of each sample was injected, and analytes sepa-
rated using a 100 mm ZIC-HILIC column with 2.1 mm ID and
3.5 mm particle size (Sequant, Umeå, Sweden). A linear gradient
was used, starting at 20% A for 2 min, followed by an increase to
50% A over 10 min, and ﬁnally a 3 min re-equilibration. Metabo-
lites of interest were measured in positive ionisation mode with
unscheduled multiple reaction monitoring events (MRMs) (Sup-
plementary Table 2), using a source temperature of 500 °C, an ion
spray voltage of 4.5 kV and a dwell time of 50 ms. Peaks were
integrated by the Quantitation Wizard within Analyst™ version
1.6 by AB Sciex Ltd. (Warrington, Cheshire, UK) and normalised
against wet tissue weight and to the intensity of the internal
standards.
2.7. Analysis of acyl-carnitines
Acyl-carnitines were measured according to the method de-
scribed by Roberts et al. [21]. Brieﬂy, 100 mL internal standard so-
lution mix (1.63 mM [D9] free carnitine, 0.3 mM [D3] acetyl carni-
tine, 0.06 mM [D3] propionyl-carnitine, 0.06 mM [D3] butyryl-car-
nitine, 0.06 mM [D9] isovarelyl-carnitine, 0.06 mM [D3] octanoyl-
carnitine, 0.06 mM [D9] myristoyl-carnitine, and 0.12 mM [D3]
palmitoyl-carnitine, Cambridge Isotope Laboratories, Andover, MA,
USA) was added to 40 mL of the organic fraction of the methanol:
chloroform extraction and the resulting mixture were dried down
under nitrogen and derivatised with 100 mL of 3 M butanolic-HCl
(Sigma-Aldrich, Louis, Missouri, USA). Samples were evaporated
under nitrogen, re-constituted and sonicated in 4:1 acetonitrile:
0.1% formic acid in water before transferring them to autosampler
vials. Samples were analysed using an AB Sciex 5500 QTRAP mass
spectrometer (AB Sciex UK Limited, Warrington, Cheshire) coupled
to an Acquity UPLC system. Mobile phase A consisted of 0.1% for-
mic acid in water, while mobile phase B was acetonitrile. Two
microliters of each sample was injected onto a Synergi Polar RP
phenyl ether column (100 mm2.1 mm, 2.5 mm) supplied by
Phenomenex (Macclesﬁeld, Cheshire, UK). The analytical gradient
started at 30% B, followed by a linear increase to 100% B over
3 min. The gradient was then held at 100% B for 5 min, after which
it was returned to the re-equilibration level of 30% B for 2 min. A
ﬂow rate of 0.5 mL/min was used throughout. Data were analysed
using the Quantitation Wizard within Analyst™ version 1.6 by AB
Sciex Ltd. (Warrington, Cheshire, UK) and normalised against wet
tissue weight and to the intensity of the internal standard.
2.8. Extraction and analysis of eicosanoids
Eicosanoids were extracted using solid phase extraction (SPE)
Waters Oasis-HLB cartridges (Waters Ltd., Elstree, Hertfordshire,
UK) as described by Roberts and colleagues [21]. SPE columns
were washed with ethyl acetate (2 mL), methanol (22 mL), and
15% methanol with 0.1% acetic acid (2 mL). Approximately 100 mg
liver tissue samples were homogenised on a TissueLyser (Qiagen
Ltd., Manchester, UK; 10 min at 30 Hz) in 1.5 mL 15% methanol
with 0.1% acetic acid. The samples were centrifuged (17,000 g,
2 min) and the supernatant loaded onto the SPE columns. Car-
tridges were washed with 1 mL 15% methanol with 0.1% acetic
acid. Analytes of interest were eluted with 0.5 mL of methanol
followed by 1 mL of ethyl acetate and immediately dried under
nitrogen. Samples were ﬁnally reconstituted in 40 mL methanol
containing 70 nM PGE2-d4 internal standard and transferred to
autosampler vials. Analysis was performed using a 4000 QTRAP
mass spectrometer (AB Sciex UK Limited, Warrington, Cheshire)
coupled to an Acquity ultra performance liquid chromatography
(UPLC) system (Waters Corp., Milford, MA). The autosampler was
Fig. 1. Summary of changes in body, liver and liver to body weight ratios. Changes in body weight (A) liver weight (B) and liver to body weight ratios (C) during the
experiment including the recovery period. (Results from the recovery period are marked with the sufﬁx’ ‘R’.) Variables were analysed using one-way analysis of variance
(ANOVA). *po0.05, **po0.01, ***po0.001.
Table 2
Clinical chemistry parameters. Abbreviations: ALP, alkaline phosphatise; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Bil, total bilirubin; CK, creatine
kinase.
Parameters Dose groups (mg/kg/day)
0 30 100 300 1000
ALT (IU/L) 74714 71715.6 77723.1 117710.38 116758.7
AST (IU/L) 115714.2 112715.1 105715.2 295**746.28 257***787.6
ALP (IU/L) 303766.4 314772.8 380*779.9 429***7105.4 815***7154
Bil (umol/L) 2.670.55 1.070.33 1.0***70 1.0***70.25 5.7*74.66
Albumin (g/L) 4672.7 50*74.7 53***73.6 53***75.1 5072.9
Glucose (mmol/L) 4.470.8 4.370.49 4.970.79 4.870.68 5.770.68*
CK (g/L) 6473.5 6273.3 6473.5 6274.9 58***74.2
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particle size, 1502 mm column (Phenomenex Macclesﬁeld,
Cheshire, UK). The gradient of mobile phase A (0.1% acetic acid in
water) and B (0.1% acetic acid in acetonitrile:methanol 80:20) is
detailed in Supplementary Table 3. The ﬂow rate was held at
0.4 mL/min. Metabolites of interest were measured in negative
ionisation mode with unscheduled multiple reaction monitoring
events (MRMs) (Supplementary Table 4). Peaks were integrated by
the Quantitation Wizard within Analyst™ version 1.6 by AB Sciex
Ltd. (Warrington, Cheshire, UK) and normalised against wet tissue
weight and to the intensity of the internal standard.
2.9. Enzyme-linked immunosorbent assay (ELISA)
An ELISA assay was carried out to proﬁle 4 cytokines: tumour
necrosis factor-alpha (TNF-α), interleukin 6 (Il-6), interferon pro-
duction regulator (IFNr) and interleukin-1 alpha (IL-1α) (Signosis
Inc, Santa Clara, CA). Approximately 50 mg of liver tissue was
homogenised in 1 mL of radio-immunoprecipitation assay (RIPA)
buffer containing cOmplete, mini protease inhibitor tablets(Sigma-Aldrich Co., Dorset, UK) and phenylmethanesulphonil
ﬂuoride (1 mM). The homogenised samples were sonicated and
centrifuged (15,000 g for 20 min at 4 °C). Protein quantiﬁcation of
the supernatant was carried out using Pierce BCA protein assay kit
(Thermo Fisher Scientiﬁc Inc., Paisley, UK) and samples were di-
luted to approximately 0.4 μg/μL total protein content. The ELISA
protocol was carried out according to the manufacturer's instruc-
tions and absorbance was measured spectrophotometrically at
450 nm using a TCAN NanoQuant Inﬁnite M200Pro spectrometer
(Tecan Group Ltd., Männedorf, Switzerland).
2.10. RNA puriﬁcation
Total RNA was puriﬁed from frozen rat liver using an RNeasy
Mini Kit (Qiagen Ltd. Manchester, UK) according to manufacturer's
speciﬁcations. Approximately 50 mg tissue, 1 mL QIAzol and a
5 mm metal bead were added to a 2 mL microcentrifuge tube. The
samples were lysed and homogenised in a TissueLyzer (Qiagen Ltd.
Manchester, UK), and subsequently incubated at room tempera-
ture for 5 min. Chloroform (200 mL) was added to each sample,
Fig. 2. Overview of gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) data from the lipid extracts of rat liver tissue
samples treated with the PPAR-pan agonist GW625019. (A) Partial least squares-discriminant analysis (PLS-DA) scores plot shows total fatty acid data from lipid extracts of
liver tissue samples with clear clustering associated with dose of the agonist. (B) Metabolic changes caused by PPAR-pan agonist GW625019 are increased γ-linoleic acid
(GLA) and dihomo-γ-linoleic acid (DGLA). Linoleic acid (LA), α-linoleic acid (ALA) and eicosapentaenoic acids (EPA) concentration were decreased. Arrows show the direction
of changes in lipid concentrations relative to control samples in red (increased) and green (decreased) respectively. (C) PLS-DA scores plot of LC–MS intact lipid data (D) and
an overview of the chain length and the saturation of changing lipids. Red circles represent the compounds which have increased, whereas blue circles show decreased lipid
species. Treatment abbreviations: C., control; Int. I., intermediate 1; Int. II., intermediate 2; R., recovery.
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3 min. The samples were centrifuged at 4 °C and 12,000 g for
15 min. The aqueous (upper) fraction containing RNA was trans-
ferred to a new tube and 1 volume of 70% ethanol was added. The
samples were vortexed, added to spin columns and centrifuged at
8000 g for 15 s to bind RNA to the membrane, with the re-
mainder of the procedure continuing as described in the RNeasy
RNA puriﬁcation kit. RNA concentration was quantiﬁed at 260 nm
using a NanoDrop 100 (Thermo Fisher Scientiﬁc Inc., Paisley, UK).
2.11. Reverse transcription and qPCR
Genomic DNA contamination was ﬁrst eliminated using the
RT2 First Strand Kit (Qiagen Ltd. Manchester, UK). Brieﬂy, 400–
500 ng RNA, diluted as required into a ﬁnal volume of 8 mL using
RNase-free water, and 2 mL Buffer GE were added to a 0.5 mL PCR
tube. The samples were then heated to 42 °C for 5 min and cooled
to 4 °C for 10 min in a PTC-200 Thermocycler (MJ Research).
Complimentary DNA was produced from the gDNA elimination
reaction using the above RT2 First Strand Kit by adding 4 mL 5
Buffer BC3, 1 mL Control P2, 2 mL Buffer RE3 and 3 mL RNase-freewater. The samples were incubated at 42 °C for 15 min followed by
95 °C for 5 min in the thermocycler and the produced cDNA pro-
duced frozen at 20 °C. For analysis of steady-state mRNA levels,
relative abundance of transcripts of interest was assessed by
quantitative-PCR in RT2 SYBRgreen Mastermix (Qiagen Ltd. Man-
chester, UK) with a StepOnePlus detection system (Applied Bios-
ciences). RT2 primer assays for rat Sod2, Gss, Gstk1, Lonp1, Tnf and
Il1α were obtained from QIAgen. Thermocycler parameters were
as follows: initial incubation, 95 °C for 10 min; with 40 cycles of
both elongation, 15 s at 95 °C; and cooling, 1 min at 60 °C. Ex-
pression levels were normalised to Rn18s using the ΔΔCT method,
and subsequently to samples of the control group to give fold-
changes.
2.12. Multivariate statistical analysis
For multivariate data processing the software package SIMCA
13 (Umetrics AB, Malmö, Sweden) was used and partial least
squares discriminant analysis (PLS-DA) was employed. Model va-
lidation was performed by cross validation using 100 random
permutations of the PLS-DA models.
Table 3
Changes in phospholipids and triacylglycerols with variable importance in projec-
tion (VIP) score equal or greater than one comparing the control to the high dose
group samples. The arrows indicate the direction of the chance. Abbreviations: LPC,
lyso-phosphocholine; PC, phosphocholine; PE, phosphoethanolamine; RT, retention
time; TG, triacylglycerol; VIP, variable importance in projection.
RT m/z VIP score ID
1.04 544.332 ↓ 1.1 LPC(20:4) LPC(20:4)
1.31 426.353 ↓ 1.1 LPE(14:0) LPE(14:0)
6.76 808.584 ↓ 1.2 PC(38:5)
6.92 808.584 ↓ 1.7 PC(38:5)
7.24 784.584 ↓ 1.7 PC(36:3) PC(18:1_18:2)
7.41 766.538 ↓ 2.0 PE(38:5)
8.85 832.581 ↓ 1.1 PC(40:7) PC(20:4_20:3)
8.86 810.600 ↓ 3.5 PC(38:4)
9.23 808.580 ↓ 1.1 PC(38:5) PC(18:0_20:5)
9.24 786.600 ↓ 3.7 PC(36:2) PC(18:1/18:1)
9.26 718.535 ↓ 1.4 PE(34:1)
13.08 813.683 ↓ 1.5 PC(37:4)
13.18 638.569 ↓ 1.2 DG(36:2)
13.19 643.525 ↓ 1.8 DG(38:5)
13.42 801.682 ↓ 1.4 PC(36:3) PC(18:1_18:2)
13.74 749.545 ↓ 1.2 TG(37:3)
14.49 818.613 ↓ 1.5 TG(48:3)
14.49 795.627 ↓ 1.8 TG(48:6)
14.50 812.653 ↓ 3.3 TG(48:6)
15.28 875.706 ↓ 1.1 TG(54:8) TG(18:2_16:0_20:6)
15.34 870.750 ↓ 1.5 TG(52:5) TG(18:3_18:2_16:0)
15.35 920.766 ↓ 1.2 TG(56:8) TG(18:2_16:0_22:6)
15.47 896.767 ↓ 2.5 TG(54:6) TG(18:1_18:2_18:3)
15.48 902.726 ↓ 1.4 TG(54:3) TG(20:1_20:1_14:1)
15.49 922.782 ↓ 1.9 TG(56:7) TG(16:1_20:4_20:2)
15.49 928.742 ↓ 1.1 TG(57:11) TG(20:0_18:0_18:4)
15.57 898.782 ↓ 2.2 TG(54:5) TG(20:3_18:2_16:0)
15.59 878.727 ↓ 2.1 TG(53:8) TG(18:0_20:1_14:0)
15.59 872.768 ↓ 4.1 TG(52:4) TG(18:2_18:2_16:0)
15.75 898.783 ↓ 1.5 TG(54:5) TG(20:3_18:2_16:0)
15.76 695.571 ↓ 1.0 TG(40:0) TG(24:0_6:0_10:0)
15.82 848.768 ↓ 2.5 TG(50:2) TG(16:0_16:0_18:2)
15.85 874.785 ↓ 2.0 TG(52:3) TG(16:0_18:2_18:1)
15.86 900.799 ↓ 1.4 TG(54:4) TG(18:1_18:1_18:3)
15.96 666.616 ↓ 1.1 DG(38:2) DG(20:0_18:2)
15.96 671.572 ↓ 1.1 DG(40:5)
16.12 902.815 ↓ 1.1 TG(54:3) TG(18:1_18:1_18:1)
16.39 904.830 ↓ 1.6 TG(54:2) TG(18:1:18:1_18:0)
16.39 884.774 ↓ 1.4 TG(53:5)
16.39 878.816 ↓ 2.9 TG(52:1) TG(16:0_18:0_18:1)
16.39 884.774 ↓ 1.4 TG(53:5)
1.79 622.401 ↑ 1.0 PC(24:0)
3.41 790.550 ↑ 1.5 PC(37:7)
5.24 830.567 ↑ 1.8 PC(40:8)
6.68 804.550 ↑ 2.2 PC(38:7)
6.98 780.550 ↑ 2.2 PC(36:5)
7.21 740.522 ↑ 4.0 PE(36:4) PE(22:4_14:0)
8.35 784.584 ↑ 1.9 PC(36:3)
8.66 760.585 ↑ 10.5 PC(34:1)
8.66 782.566 ↑ 3.4 PC(36:4) PC(16:0_20:4)
8.82 782.566 ↑ 1.2 PC(36:4) PC(16:0_20:4)
8.84 760.585 ↑ 3.0 PC(36:4) PC(18:1_18:3)
9.54 768.552 ↑ 3.7 PE(38:4)
9.77 768.553 ↑ 1.4 PE(38:4)
11.45 788.615 ↑ 2.9 PC(36:1) PC(18:1_18:0)
11.74 788.616 ↑ 1.4 PC(36:1) PC(18:1_18:0)
13.13 577.518 ↑ 1.1 DG(33:3)
13.14 617.510 ↑ 1.7 DG(36:4)
13.61 647.457 ↑ 1.8 TG(37:3)
13.81 670.608 ↑ 1.3 TG(37:0)
14.35 672.625 ↑ 1.2 DG(39:6)
14.50 833.582 ↑ 1.2 TG(51:8)
14.50 817.609 ↑ 1.7 TG(50:9)
15.81 854.726 ↑ 1.3 TG(51:6)
16.11 850.784 ↑ 2.1 TG(50:1) TG(16:0_16:0_18:1)
16.11 876.800 ↑ 9.5 TG(52:2) TG(16:0_18:1_18:1)
16.11 882.759 ↑ 2.9 TG(53:6)
Z. Ament et al. / Free Radical Biology and Medicine 95 (2016) 357–3683623. Results and discussion
3.1. PPAR-pan treatment causes classic dose dependent response
A discontinued PPAR-pan activator [22] was administered to
male Sprague–Dawley rats (Crl: CD (SD) strain), 12 animals per
group, by daily oral gavage at 30, 100, 300, 1000 mg/kg/day for 13
weeks (Table 1). Food intake was normal in all dose groups except
in the high dose group, where food intake was reduced at week 12
by 20%. The most pronounced effect on body weight was observed
in animals given 1000 mg/kg/day with a total body weight loss of
22% (po0.001). Liver weights increased with dose by 20%, 44%,
54%, and 65% (po0.001) at 30, 100, 300 and 1000 mg/kg/day, re-
spectively, compared to controls. After the withdrawal of treat-
ment in the recovery groups, animals gained total weight during
the 4 week recovery period and the liver weights decreased back
to control values (Fig. 1). The, reductions in food consumption
noted at 1000 mg/kg/day in Week 12 correlate with the observed
reduction in bodyweight, suggesting that weight loss is associated
with decreased food intake, as well as the PPAR-pan agonist ac-
tivity, increasing oxidation of carbohydrates and fatty acids.
Plasma aspartate aminotransferase (AST), plasma alkaline
phosphatase (ALP), and albumin concentrations [23] were all in-
creased with treatment reﬂecting liver damage compared to con-
current controls in animals given doses of 300 or 1000 mg/kg/day,
respectively. Other changes include increased alanine amino-
transferase (ALT) at the highest dose level and total bilirubin levels
(Bil) in all treatment groups (Table 2).
Creatine kinase (CK) concentrations were increased in animals
at the 1000 mg/kg/day dose (po0.001) presumably reﬂecting
muscle myopathy. There were no clear dose response variations in
the urinalysis parameters although an increase in glucose con-
centrations (po0.05) was observed at the highest dose level by
week 12.
Microscopic observations detected hepatocyte hypertrophy,
which increased in severity in the high dose groups. This is a well-
recognised response to the proliferation of sub-cellular organelles,
including peroxisomes. In addition, the heart and muscles (skele-
tal, soleus and gastrocnemius) showed evidence of myopathy, in-
creasing in severity with dose. There was evidence of fat mobili-
sation as seen by decreased adipocyte size (abdominal fat), mac-
rovesiculation in brown fat and microevesiculation in the adrenal
glands (Supplementary Table 1). Following withdrawal of the
compound the incidence and severity of both histological and
clinical chemistry changes decreased, suggesting that they were
transitory in nature.
3.2. Lipidomic remodelling indicates inﬂammation in a dose depen-
dent manner in response to PPAR-pan agonist
Hepatic total fatty acids were measured by GC–MS (Supple-
mentary Data 1 [24]). For an overview of total fatty acid changes
multivariate data analysis was performed and a PLS-DA model was
constructed to assess the dose response (R2¼73%, Q2¼45%). The
highest dose group clustered separately while there was a linear
relationship going from the low to intermediate 2 dose levels
showing a dose dependent change in the metabolite concentra-
tions. Furthermore, the recovery groups from both the two inter-
mediate and the high dose groups clustered with the control
samples (Fig. 2A). Fatty acids were analysed by one way ANOVA
with Bonferroni post-tests. The investigated PPAR-pan agonist
caused a decrease in relative concentrations of the main n3 fatty
acids α-linoleic acid (ALA,18:3 n3) (po0.01 at 30 mg/kg/day and
po0.001 at dose levels 100, 300 and 1000 mg/kg/day) and eico-
sapentaenoic acid (EPA, 20:5 n3) (po0.05) at the two inter-
mediate dose levels (100 and 300 mg/kg/day). The third main n3
Fig. 3. Overview of acyl-carnitine and of aqueous metabolite changes measured in the extracts of liver tissue samples treated with the PPAR-pan agonist. (A) Partial least
squares-discriminant analysis (PLS-DA) scores plot and (B) loadings plot of acyl-carnitine changes. (C) PLS-DA scores plot and (D) loadings plot of aqueous metabolite
changes. Treatment abbreviations: C., control; Int. I., intermediate 1; Int. II., intermediate 2; R., recovery. Metabolite abbreviations: 3PG, 3-phosphoglycerate; ADP, adenosine
diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; CMP, cy-
tidine monophosphate; FAD, ﬂavin adenine dinucleotide; GDP, guanosine diphosphate; GMP, guanosine monophosphate; GSH, glutathione; GSSG, oxidised glutathione; GTP,
guanosine triphosphate; NAD, nicotineamide adenine dinucleotide; PCr, phosphocreatine; PEP, phosphoenolpyruvate; SAH, S-adenosyl-homocysteine; SAM, S-adenosyl-
methionine; UMP, uridine monophosphate.
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signiﬁcant decrease. However, the n3 or omega-3 index
(EPAþDHEA expressed as the percentage of total identiﬁed fatty
acids) decreased (po0.01) at the highest dose level. Ratios of n6/
n3 fatty acids increased at all dose levels (po0.001). Arachidonic
acid (AA n6) and eicosapentaenoic acid (EPA n3) are parent
compounds for the production of inﬂammatory mediators often
with opposing metabolic and functional properties. The class of n3
fatty acids are reported to have effects preventing proliferation and
initiating apoptosis [25,26] whereas n6 fatty acids are thought to
have opposing effects through eicosanoids formed by AA which
contribute to inﬂammation and cell proliferation [25,26].
Relative concentrations of γ-linoleic acid (GLA, 18:3 n6) and
dihomo-γ-linoleic acid (DGLA, 20:3 n6) were increased whereas
linoleic acid (LA, 18:2 n6) concentrations decreased at all dose
levels (Fig. 2B). Linoleic acid (LA, n6) is metabolised by Δ6 de-
saturase to form gamma-linoleic acid (GLA n6) which is rapidly
elongated to DGLA. DGLA is further desaturated to AA by Δ5 de-
saturase but this enzyme has limited activity in rodents and this
caused DGLA to accumulate more rapidly than AA in the present
study when the pathway was activated by the PPAR-pan agonist.
Both the Δ5 desaturase and the Δ6 desaturase are transcriptional
targets of PPAR-α and PPAR-δ [27,28].Monounsaturated fatty acid (MUFA) concentrations increased
at the highest dose (po0.01), and polyunsaturated (PUFA) con-
centrations decreased at the intermediate dose 2 (po0.01) and
the highest dose (po0.001) levels. In addition, at the highest dose,
saturated fatty acids (SFA) myristic acid (14:0) pentadecanoic acid
(15:0) and heptadecanoic acid (17:0) decreased. Decreased odd
chain saturated fatty acids are indicative of decreased food intake
at the highest dose, whilst decreased PUFAs reﬂect differences in
lipid oxidation rate where unsaturated lipids are preferentially
oxidised with respect to saturated fatty acids (SFA) or MUFAs. Si-
milar results have been reported for PPAR-δ agonists [13].
Overall, PPAR-pan exposure caused a decrease in both essential
PUFAs (18:2 n6 and 18:3 n3) indicating an increase in the Δ6
desaturase activity at all doses. Additionally, moderate decreases
in n3 and increases in n6 fatty acids were detected, in a dose
dependent manner, indicative of liver inﬂammatory processes. The
effects were transitory in nature.
3.3. Interconnected signalling networks contribute to liver enlarge-
ment and potential DNA damage
The effects of liver enlargement and fat mobilisation as de-
tected by microscopy were further investigated using an LC–MS/
Fig. 4. Eicosanoid changes of rat liver tissue samples treated with the PPAR-pan agonist. Bar charts illustrate the changes in relative concentration of those signiﬁcantly
changing species of intermediate dose II (grey) and high dose (black) samples, compared to control (white). Statistical analysis was carried out using one-way analysis of
variance (ANOVA) with Bonferoni’s post-test. Values show mean7standard deviation where n¼12; *po0.05 **po0.01***po0.001. Abbreviations: C., control; AA, ara-
chidonic acid; DHET, dihydroxyeicosatrienoic acid; EET, epoxyeicosatrienoic acid; Int. I., intermediate 1; Int. II., intermediate 2; PG, prostaglandin; R, recovery.
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and triglycerides (TGs) (Supplementary Data 2 [24]). First PLS-DAwas
used to gain an overview of the intact lipid changes (Fig. 2C). Again,
the highest dose group clusters separately, the low to two inter-
mediate dose levels showed a dose dependent effect. In agreement
with the microscopic observations the majority of metabolites clas-
siﬁed as PLs increased, whereas TGs decreased in concentration
(Fig. 2D). Eighty four metabolites were identiﬁed as signiﬁcant, based
on their variable impotence in projection (VIP) score which estimates
the importance of each variable in the PLS-DA projection. The PLS-DA
model variables with VIPZ1 were selected and further characterised
based on their fragmentation patterns (Table 3). The report of a
general decrease in TG concentrations and an increase in PLs are inagreement with ﬁndings describing response to PPAR-δ agonists re-
ported by Roberts and co-workers previously [13] and with ﬁndings
reported as a response to PPAR-α agonists [19]. In addition, the in-
creases in PL concentrations may potentially provide for the required
biomass during membrane development and organelle proliferation
of the smooth endoplasmic reticulum (sER) and peroxisomes, effects
known to be induced by PPAR-α activation [29]. Since PLs are also
natural ligands of LRH2 [30], a nuclear reception known to induce
proliferation and hyperplasia [31], it is most likely that LRH2 also
contributes to the effects observed to those directly driven by the
PPAR-pan agonist GW625019.
Carnitine and acyl-carnitines were measured by LC–MS/MS to
investigate whether the decreased TG concentrations are reﬂected
Table 4
Relative concentration changes in the measured eicosanoids. Signiﬁcant changes as
determined by ANOVA with Bonferoni’s post test for multiple comparisons labelled
↑po0.05, ↑↑ po0.01, ↑↑↑ po0.001 for increased and ↓po0.05,↓↓ po0.01, ↓↓↓
po0.001 (n¼12). Abbreviations: AA, arachidonic acid; DGLA, dihomo-γ-linolenic acid;
DHEA, docosahexaenoic acid; DHET, dihydroxyeicosatrienoic acid; DHOME, dihydrox-
yoctadecenoic acid; EET, epoxyeicosatrienoic acid; HDoHE, hydroxydocosahexaenoic
acid; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE,
hydroxyoctadienoic acid; LT, leukotriene; ODE, octadienoic acid, PG, prostaglandin;
THET, trihydroxyeicosatetraenoic acid; THF, tetrahydrofuran; TX, thromboxane.
Inter-
mediate 2
High
dose
Inter-
mediate 2
High
dose
1 11(12)-EET ― ― 24 8,9-DHET ― ↓
2 11,12,15-THET ― ↑↑↑ 25 8-HETE ― ―
3 11,12-DHET ↓↓↓ ↓↓↓ 26 8-iso-
PGE2
↓↓ ↓↓
4 11-HEPE ↓↓↓ ↓↓ 27 8-
isoPGF2a
↓ ↓↓
5 11-HETE ― ― 28 9(10)-
EpOME
↓ ↓↓
6 12(13)-EpOME ↓↓ ↓↓ 29 9,10,13-
TriHOME
― ―
7 12,13-DHOME ↓↓↓ ↓↓ 30 9,10-
DHOME
↓↓↓ ↓↓↓
8 12-HEPE ↓↓↓ ↓↓↓ 31 9,12,13-
TriHOME
― ↓
9 12-HETE ― ↓↓ 32 9-HODE ↓ ↓↓
10 13-HDoHE ↓ ↓↓ 33 9-oxo-
ODE
↓ ↓↓
11 13-HODE ↓ ↓↓ 34 AA ― ―
12 13-oxo-ODE ― ↓ 35 DHEA ― ―
13 14(15)-EET ― ― 36 DGLA ↑ ↑↑↑
14 14,15-DHET ― ― 37 Lipoxin A4 ― ↓
15 15-deoxyPGJ2 ↑↑↑ ↑↑↑ 38 LTB4 ― ―
16 15-HETE ― ― 39 PGB2 ↑↑↑ ↑↑↑
17 15-oxo-EET ― ― 40 PGD2 ― ↓
18 19-HETE ― ― 41 PGE2 ↓↓ ↓↓
19 20-HETE ― ― 42 PGF2a ↓ ↓
20 5(6)-EET ― ↑ 43 THF diols ― ―
21 5,6-DHET ― ↓ 44 TXB2 ― ―
22 5-oxo-EET ― ―
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Multivariate data analysis was used to generate a PLS-DA model
(R2¼87%, Q2¼58%) producing an overview of the changes in car-
nitine species (Fig. 3A). An increase in the concentrations of all
measured carnitines was detected with an exception of octenoyl-
carnitine (C8:1) which decreased at all dose levels. Treatment-
related increases in the concentrations of free carnitine, acetyl-
carnitine (C2), propionyl-carnitine (C3), palmitoyl-carnitine (C4) as
well as increased concentrations of stearoyl- (C18:0), oleyl-
(C18:1), linoleyl- (C18:2) and palmitoyl- (C16:0) carnitines were
observed at all dose levels whilst the recovery groups showed
reversibility (Fig. 3B).
Increased concentrations of free- and acyl-carnitine derivatives
indicates an increase in β-oxidation, and the proﬁle was the
complete opposite to the carnitine proﬁle of hearts from ob/ob
mice during high fat substrate excess as reported by Wang et al.
[32]. Increased concentration of long-chain acyl-carnitine species
could be suggestive of altered long chain 3-hydroxy acyl-CoA de-
hydrogenase (LCHAD), and very long chain acyl-CoA dehy-
drogenase (VLCAD) which are likely to be an effect of increased
peroxisomal activity reﬂecting peroxisome proliferation. Another
possible source of long-chain acyl-carnitines is TG catabolism, as
the fatty acid chains in TG species with decreased concentrations
are in agreement with the carnitine increases (both saturated and
unsaturated C18 and C16 fatty acids). Accumulation of long-chain
carnitines in plasma have also been detected in type 2 diabetes
mellitus [33] where incomplete β-oxidation is suggested to be the
cause of increased long-chain species, and it has been suggestedthat overproduction of long chain carnitines can lead to mi-
tochondrial overload and mitochondrial dysfunction [34].
The production of metabolites by oxidation is also exacerbated
due to increased mitochondrial and peroxisomal activity. Excessive
generation of these metabolites can lead to oxidative stress, DNA
damage and eicosanoid production. To study the effects of a dis-
continued PPAR-pan agonist on oxidative metabolite production
the aqueous fractions of liver cell extracts were analysed (Sup-
plementary Data 4 [24]). The highest dose group separated
strongly form controls (Fig. 3C), with the discriminatory metabo-
lites related to processes of oxidation and methionine-cycle and
1-carbon metabolism [35]; intermediates such as oxo-methionine,
methyl-cytosine and adenosyl-methionine (SAM) concentrations
all increased.
In addition nucleic acids cytosine, uridine and uracil were all
decreased in concentration following PPAR-pan agonist treatment
(Fig. 3D). The sulphur of methionine is particularly prone to oxi-
dation, and forms oxo-methionine, while methionine is also nee-
ded to form SAM which serves as a methyl donor in various re-
actions. Cytosine receives its methyl group from SAM during DNA
methylation and in turn SAM forms S-adenosyl-L-homocysteine
(SAH). Methyl-cytosine is the main site of methylation for epige-
netic modiﬁcations, and therefore the increased concentrations of
methyl cytosine and SAM induced by the drug treatment suggests
epigenetic reprogramming following exposure to the PPAR-pan
agonist. Furthermore, increased concentrations of 3-phosphogly-
cerate (3PG) and phosphoenolpyruvate (PEP), and acetyl- and
malonyl-CoA indicate stimulated glycolysis which were shown to
be up-regulated in PPAR-δ agonist-treated cells [2]. While mal-
onyl-CoA is known to inhibit CPT-1 in the liver and hence reduce
β-oxidation, this does depend on the physiological status of the
liver [36], with CPT-1 being partly under the regulation of PPAR-α
[37], and thus, malonyl-CoA inhibition of CPT-1 may be overcome
by a greater upregulation of the expression of the enzyme.
To determine the inﬂammatory state of the liver caused by this
disruption of lipid homeostasis, a range of eicosanoids were
measured in the control and the two highest dose level groups
(Supplementary Data 5 [24]). A targeted LC–MS/MS approach was
used and detected decreases in the concentrations of pros-
taglandins (PG) PGE2, PGD2, and PGF2 and increases in the con-
centrations of PGB2 and 15-deoxy PGJ2. Concentrations of dihy-
droxyeicosatrienoic acids (DHETs) decreased while no signiﬁcant
changes could be measured in the corresponding epoxyeicosa-
trienoic acid (EET) concentration (Fig. 4). Changes in the con-
centrations of all measured metabolites are summarised in Table 4.
The PPARs play a critical physiological role as lipid sensors and
regulators of lipid metabolism across the whole body. Poly-
unsaturated fatty acids (PUFAs) such as arachidonic acid and
docosahexaenoic acid (DHEA) are endogenous activators of PPARs,
linking eicosanoid and related lipid mediator signalling to the
PPAR system. High-afﬁnity physiological ligands for the PPARs are
currently unknown, but fatty acids and their metabolites can act as
activating ligands for PPARs. For example, COX-related metabolites
such as prostaglandin D2 (PGD2) and 15-deoxy Δ12,14pros-
taglandin J2 (15d-PGJ2), activate PPAR-γ [38]. Endogenous activa-
tors of PPAR-α include hydroxyeicosatetraenoic acid (8(S)-HETE)
and several unsaturated fatty acids, linoleic acid (LA, 18:2 n6), γ-
linoleic acid (GLA, 18:3 n6), oleic acid (18:1, n9), as well as
arachidonic acid (AA, 20:4 n6). Examples of endogenous PPAR-δ
ligands include prostaglandin D2 (PGD2), PGA1 and dihomo-γ-li-
noleic acid (DGLA, 20:3 n6) [39]. Endogenous PPAR ligands al-
tered by the PPAR-pan agonist include PGE2↓, PGD2↓, PGF2↓,
PGB2↑, 15D-PGJ2↑ and DGLA↑ suggesting that these signalling
lipids could directly stimulate the PPAR system, despite their
low afﬁnity compared to synthetic agonists, because of their high
local concentration within the cell. Their low afﬁnity may be
Fig. 5. The effects of PPAR-pan induction in the expression of proliferative (superoxide dismutases-2, SOD2), oxidative damage ((Glutathione-S-transferase-kappa-1
(GST-κ-1), glutathione synthase (GSH synthase), Lon protease-1 (LONp1)), and inﬂammatory (tumour necrosis factor-alpha (TNF-α), Interleukin-6 (Il-6), interferon pro-
duction regulator (IFNr) and Il-1-α) target genes and/or proteins in rat liver tissues. (A) Increased expression of SOD2, GST-κ-1 and (B) increased expression of Lonp-1 was
detected, whereas levels of TNF-α and Il1-αmRNA expression decreased as measured by real time quantitative PCR assay. We used 18 s as a control for RNA loading. (C) PPAR-
pan dependent inhibition of TNF-α, Il-6, IFNr and Il-1-α protein expression in determined by ELISA assay.
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within cells, in favour of achieving intracellular concentrations
high enough for receptor mediation.
Other measured changes in eicosanoid levels include decreased
concentrations of several dihydroxyeicosatrienoic acids (DHETs)
while changes were not detected in the corresponding epox-
yeicosatrienoic acids (EETs). EETs are synthesised from AA through
epoxygenases, primarily CYP2C and 2J classes in the ER. EETs are
also stored in phospholipids, in the sn-2 position of PC,PE and PI
and are hydrolysed (much like arachidonic acid) from PLs by
phospholipase A2 and released to the extracellular ﬂuid as DHETs
[40]. EETs are converted to DHETs in a reaction catalysed by so-
luble epoxide hydrolase (sEH) which conversion attenuates their
anti-inﬂammatory effects. DHETs are either inactive or minimally
active compared with corresponding EETs although DHETs have
been found to mediate gene expression levels of both PPAR-α and
PPAR-γ [40].
3.4. Gene expression changes conﬁrm an increased oxidative
environment
To conﬁrm the inﬂammatory status of the PPAR-pan dosed liver
an ELISA assay was carried out proﬁling 4 cytokines: tumour ne-
crosis factor-alpha (TNF-α), Interleukin 6 (Il-6), interferon pro-
duction regulator (IFNr) and Interleukin-1 alpha (IL-1α). Four
samples were selected from the control, intermediate-2 and the
intermediate-2 recovery groups and measured in duplicate using12 strips each containing 4 different antibodies. The expression of
TNFa and Il-1a were further analyse by RT-PCR.
In addition, six substrates were analysed by RT-PCR for re-
presentative genes which relate to inﬂammation (tumour necrosis
factor-alpha (TNF-α), Interleukin-1 alpha (Il-1-α)) proliferation
(superoxide dismutases-2, SOD2) and oxidative damage (Lon
protease-1 (LONp1), Glutathione-S-transferase-kappa-1 (GST-κ-1),
glutathione synthase (GSH synthase)).
Our results show an increase in the markers of oxidative da-
mage markers Lon protease (LONp), Glutathione-S-transferase-
kappa-1 (GST-κ-1), whilst no change was detected in GSH syn-
thase expression (Fig. 5A), and cytokines showed a reduction in
the dosed group samples at both the RNA and protein levels
(Fig. 5B and C).
Our results indicate an environment, where oxidative damage
is increased which is in agreement with metabolomics and lipi-
domics ﬁndings, whereas levels of cytokines were found to de-
crease. It has been reported, that certain PPAR-γ ligands, especially
15-deoxyPGJ2, antagonise the expression of TNF-α and IL-6 in
response to macrophage activation [41,42]. Furthermore, the ad-
ministration of PPAR-α agonists have been shown to reduce the
activity of nuclear factor-κB (NF-κB) leading to a loss in cytokine
production [43]. It is also widely accepted, that oxidative stress
induced activity promotes the production of a number of pro-in-
ﬂammatory cytokines, which can contribute to the pathology of
many disease states [44]. The dichotomy between the increase in
several oxidative stress markers (LONp, GST-κ-1 oxo-methionine,
Z. Ament et al. / Free Radical Biology and Medicine 95 (2016) 357–368 367methyl-cytosine, SAM, acyl-carnitines, and eicosanoids) and the
decrease of inﬂammatory cytokine markers points to additional
signalling pathways which contribute to the regulation of in-
ﬂammatory metabolite production. Our results indicate, that an
important consequence of PPAR-pan activation may be functioning
to limit the production of inﬂammatory mediators in the presence
of increased oxidation. Reducing inﬂammation is likely to limit the
production of inﬂammatory molecules (including several oxidised
lipids and pro-inﬂammatory eicosanoids) which would further
exacerbate hypertrophy and increase hepatic leakage enzyme le-
vels in the plasma such as ALT and AST.4. Conclusions
In this study we have applied a combined metabolomic and
lipidomic screen to investigate changes induced by a discontinued
PPAR-pan agonist in male SD rat livers. The livers of treated ani-
mals exhibited a classic dose-dependent phenotype indicative of
sub-cellular organelle proliferation, including increased weight,
hepatocyte eosinophilia and hypertrophy. Mechanistic studies
have previously described the observed hypertrophy as a con-
sequence of proliferation of peroxisomes and smooth ER, due to
the combined activation of PPAR-α and PPAR-δ.
From the work described here, the proliferation is in part as-
sociated with alterations in the eicosanoid proﬁle. While stimu-
lation of PPAR-α and PPAR-δ both increase fatty acid oxidation,
reducing triglycerides which might be seen as a favourable re-
sponse, the agonist also increases the production of metabolites
related to processes of oxidation which are associated with in-
ﬂammation and DNA damage. In particular several inﬂammatory
eicosanoids (prostaglandins) are altered in concentration.Acknowledgements
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